Experimental and clinical studies demonstrated that the renin-angiotensin system (RAS) affects the pathogenesis of atherosclerosis and prognosis of coronary heart disease (CHD). The aim of this study was to investigate the genotype distribution and the allele frequencies of three RAS genes polymorphisms and their effects on premature CHD in a Turkish population.
Introduction
Cardiovascular disease (CVD) is a major public health problem in many societies. According to the most important epidemiological investigation in the Turkish population, the Coronary Heart Diseases Risk Factors in Turkish Adults (TEKHARF) study, cardiovascular disease is the leading cause of mortality in Turkey. 1 Several types of CVD have a genetic basis, or at least a genetic component. It has been estimated that about 50% of the variability of the major risk factors for coronary heart disease (CHD) is genetic. Environmental factors, such as diet, also influence CVD and may interact with genetic factors to modulate risk.
Over the past decade, much interest has developed in the role of the renin-angiotensin system (RAS) in CVD. The RAS is not only essential in controlling cardiovascular haemodynamics and homeostasis, but also plays an important role in the development of CHD.Three major components of the RAS are angiotensinogen (AGT) the precursor of angiotensin I (Ang I); angiotensin-converting enzyme (ACE), which converts Ang I to angiotensin II (Ang II), the crucial biologically active product of the RAS; and the Ang II type-1 (AT 1 )-receptor, the cell surface receptor for Ang II. 2 Experimental and clinical studies demonstrated that the RAS affects the pathogenesis of atherosclerosis and prognosis of coronary artery disease. [3] [4] [5] [6] Previous studies have shown that the DD genotype of the ACE gene is associated with the development of left ventricular hypertrophy, myocardial infarction (MI) and remodelling. The TT genotype of the AGT gene is an independent risk factor for CHD, 7 and individuals with AT 1receptor CC genotype would be at increased risk of MI. 8 In this study, we planned to investigate the genotype distribution and the allele frequencies of ACE, AGT and AT 1 -receptor gene polymorphisms and their effects on premature CHD in Turkish population.
Materials and methods
The ACE,AGT and the AT 1 -receptor gene polymorphism was analysed in 115 unrelated Turkish patients with a diagnosis of premature CHD, who were admitted to the Cardiology Department of the three centres in the Aegean region of West Turkey. The control group consisted of 128 unrelated healthy subjects without a history of CHD. The study was approved by the Ethics Committee of the Celal Bayar University hospital, and all subjects provided written informed consent. The inclusion criteria for the patients were: 1) age at the time of CHD diagnosis 55 years or less in men and 65 years or less in women; 2) stenosis of at least 50% in a major coronary artery, or one of their branches, as determined by angiography.The extent of disease was defined as the number of arteries with stenosis at least 50% as single or multiple vessels. The coronary angiography was performed by Judkin's method at the Catheterization Laboratories. Diagnosis of MI was ascertained from patients records using the WHO criteria 9 based on symptoms, elevation in cardiac enzymes or electrocardiographic changes. All patients provided information about coronary risk factors, such as diabetes mellitus, hypertension, hypercholesterolaemia and cigarette smoking. Triglycerides, total cholesterol, highdensity lipoprotein (HDL) and low-density lipoprotein (LDL) levels were measured by conventional methods of clinical chemistry. Arterial hypertension was defined as systolic blood pressure >140 mmHg and/or diastolic blood pressure >90 mmHg on more than one occasion. Patients with a history of diabetes or basal glycaemia >120 mg/dl were defined as diabetic. Smoking habit from all subjects was defined as a daily intake of more than five cigarettes. Body mass index (BMI) was defined as increased when >25 kg/m 2 .A familial history of CHD was determined by interviewing patients and controls.
Genetic analysis
Genomic DNA was extracted from 200 µl of EDTAanticoagulated peripheral blood leucocytes, using the QUIAmp Blood Kit (QUIAGEN, Ontaria Canada, Cat. no:51106). Amplification of DNA for genotyping the ACE I/D polymorphism was carried out by polymerase chain reaction (PCR) in a final volume of 15 µl containing 200 µM dNTP mix, 1.5 mM MgCl 2 , 1x Buffer, 1 unit of AmpliTaq polymerase (PE Applied Biosystems) and 10 pmol of each primer. The primers used to encompass the polymorphic region of the ACE were 5′-CTG-GAGACCACTCCCATCCTTTCT-3′ and 5′-ATGTG-GCCATCACATTCGTCAGAT-3′. 10 DNA was amplified for 35 cycles, each cycle comprising denaturation at 94°C for 30 seconds, annealing at 50°C for 30 seconds, extention at 72°C for 1 minute with final extention time of 7 minutes.The initial denaturation stage was carried out at 95°C for 5 minutes.The PCR products were separated on 2.5% agarose gel and identified by ethidium-bromide staining. Each DD genotype was confirmed through a second PCR with primers specific for the insertion sequence. 11 To analyse AGT M235T polymorphism we PCRamplified genomic DNA with primers 5′-GAT-GCGCACAAGGTCCTG-3′ and 5′-CAGGGTGCT-GTCCACACTGGCTCGC-3′, respectively. PCR consisted of 50 mM KCl, 2.5 mM MgCl 2 , 10 mM Tris-HCl (pH 9.0), 0.1% Triton X-100, 100 µM of dNTP and 0.5 U of Taq DNA polymarase in a total volume of 50 µl. After an initial denaturation at 94°C, followed by 25 cycles of 1 minute at 94°C, 1 minute at 61°C and 1 minute 72°C. PCR products were digested with the restriction enzyme SfaNI and electrophoresed on a 3% agarose gel. 12 The AT 1 -receptor A1166C polymorphism was analysed with primers 5′-GCAGCACTTCACTAC-CAAATGAT-3′ and 5′-TGTTCTTCGAGCAGCCGT-3′ as previously described. 13 
Statistical analysis
Statistical analysis was carried out with SPSS program for Windows 98 version 10.0 (SPSS Inc., Chicago, IL, USA). Variables are presented as means±SD. A p value of 0.05 or less was considered as significant. Univariate analysis was performed by Chi-squared, odds ratios (OR) and Mann Whitney U test.The Hardy-Weinberg's equilibrium for genotype distribution was estimated by the chi-squared test. We also calculated the genotypic OR for premature CHD and their 95% confidence interval (CI) with two-tailed p values, using multiple logistic regression analysis adjusted for family history of CHD, diabetes, hypertension, total cholesterol, triglycerides, HDL-C, LDL-C, BMI and smoking habit. The Backward Wald method was used for logistic regression analysis.
Results
The study population consisted of 115 patients with premature CHD and 128 control subjects. The clinical characteristics of the patients and controls are summarised in Table 1 . The patients (77%) and controls (78%) were predominantly men.The patient group had a higher prevalence of hypertension, diabetes, smoking and family history of premature CHD than the controls.The patients also had higher total cholesterol, LDL-C and triglycerides levels and lower HDL-C level (p<0.05). According to our results, family history, hypertension, diabetes, smoking, obesity, high total cholesterol, LDL-C and triglycerides levels and low HDL-C conferred an increased risk of premature CHD ( Table 2) . The distribution of the ACE I/D, AGT T/M and AT 1 -receptor A/C genotypes and allele frequencies in patients and controls were compatible with Hardy-Weinberg's equilibrium, as presented in Table 3 (ACE I/D: p=0.007, X 2 =9.835;AT 1 -receptor A/C p=0.011, X 2 =9.089; AGT T/M: p=0.076, X 2 =5.145). The patient group showed a significantly increased frequency of the ACE D allele compared with controls (0.652 vs. 0.508 p=0.0001).
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There was a significant association between the DD genotype and premature CHD [ACE DD vs. ID and II; OR=2.82 (CI 95% 1.33-2.91, p=0.002)]. Also, we observed increased premature CHD risk associated with higher frequencies of the AGT-MM genotype in patients when compared with controls [AGT MM vs. TT and MT, OR=1.92 (CI 95% 1.11-3.33, p= 0.018)] and a significant association between AT 1 -receptor AA genotype and decreased risk of premature CHD [AT 1 -receptor AA vs. AC and CC, OR=0.57 (CI 95% 0.34-0.95, p=0.03)] ( Table 4) .
By multiple regression analysis, family history of premature CHD, smoking, diabetes, hypertension, obesity and ACE DD genotype were independent risk factors for CHD. The patients with ACE DD genotype had a 2.7-fold higher risk of CHD when compared with the control group [OR= 2.74 (CI 95% 1.39-5.42, p=0.004)] ( Table 5 ).
The effect of the ACE DD genotype on the risk of premature CHD was higher in AT 1 -receptor C allele carriers.The odds ratios for premature CHD associated with the ACE DD genotype were considered as 2.95 (CI 95% 1.35-6.51, p=0.006) in AT 1 -receptor AC heterozygotes and 8.23 (CI 95% 1.00-67.95, p=0.021) in AT 1 -receptor CC homozygotes.The effect of ACE DD genotype on the risk of premature CHD was higher in AGT MM genotype subjects (ACE DD and AGT MM: OR=3.75 [CI 95% 1.60-8.77, p=0.001]) ( Table 4 ).
The ACE, AT 1 -receptor and AGT genotypes were not associated with the number of affected PAPER vessels (p>0.05). In the logistic regression analysis, there were no associations between these polymorphisms and the diseased vessels.
Discussion
This study investigated the association of ACE AT 1receptor and AGT gene polymorphisms with premature CHD in a Turkish population. We demonstrated that increased premature CHD risk is associated with higher frequencies of the ACE DD and AGT MM genotypes. Also, we show that the subjects with AT 1 -receptor AA genotype have a lower risk of developing premature CHD. In addition, our results suggested that family history of premature CHD, smoking, diabetes, hypertension, obesity and ACE DD genotpye were independent risk factors for the development of premature CHD CHD is a multifactorial disease with a clear genetic predisposition and environmental risk factors. Similarly, cardiovascular risk factors, such as diabetes mellitus, dyslipidaemia, hypertension and obesity may have both genetic and environmental contributors. 14 Premature CHD is known to have a particularly strong genetic component. Previous epidemiological data has suggested that genetic factors are more likely to affect young rather than old people. 15 In this study, there was a 2.7-fold increased independent risk of premature CHD in patients with the ACE DD genotype.This finding is consistent with some other previous studies performed in Caucasian populations. 13, [16] [17] [18] [19] Numerous studies in different populations have shown that the AGT T allele frequency is higher in CHD patients. 7, [20] [21] [22] In contrast to these studies, our results show that the risk of premature CHD in subjects with the AGT MM genotype was significantly higher when compared with individuals not carrying the M allele. This result confirms that the M allele is an independent risk factor for MI, as reported by Fernández-Arcás et al. 23 Also, there was a synergistic effect between ACE DD and AGT MM genotypes in the development of premature CHD. In a previous study from Turkey, Atac et al. found that the frequencies of AGT TT/TM/MM genotypes were 0%, 82.5% and 17.5%, respectively. 24 In addition, Ermis et al. showed that the AGT T235M polymorphism was not related to early MI in a Turkish population. 19 Nevertheless, the final phenotype of a complex disease such as premature CHD originates from the interaction of environmental factors, cardiovascular risk factors and ethnicity.
In a study of Japanese CHD patients, the C allele of the AT 1 -receptor C was found to be associated with increased severity of CHD. 25 However, other studies found no significant difference in the genotype distribution or allele frequencies for the AT 1 -receptor A/C polymorphism. 13, [26] [27] [28] In the present study, we observed a higher AT 1 -receptor A allele frequency in our study population. In addition, a significant association between AT 1 -receptor AA genotype and decreased risk of premature CHD was found. Our results suggest that the AT 1receptor C allele is responsible for the risk associ-ated with ACE DD genotype as described in the ECTIM study 29 and other studies. 13, 20 These results might suggest that the ACE D allele is associated with the development of premature CHD, and that the AT 1 -receptor C allele makes a synergistic contribution to the risk of premature CHD.
In conclusion, our study indicates a synergistic contribution of ACE DD and AGT MM polymorphisms to the development of premature CHD in a Turkish population. RAS gene polymorphisms appear to play a role in the development of premature CHD, together with traditional risk factors. Identification of the genetic predispositions. Determining the risk will improve the results of diagnostic and therapeutic interventions and reduce health expenditures. 
